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ABSTRACT
Objectives: To pool clinical trials of similar design to
assess overall sensitivity and specificity of ioflupane
I123 injection (DaTSCAN or ioflupane (123I)) to detect
or exclude a striatal dopaminergic deficit disorder
(SDDD), such as parkinsonian syndrome and dementia
with Lewy bodies.
Design: Pooled analysis of three phase 3 and one
phase 4 clinical trials. These four trials were selected
because they were the four studies used for the US
new drug application to the Food and Drug
Administration (FDA).
Setting: Multicentre, open-label, non-randomised.
Participants: Patients with either a movement
disorder or dementia, and healthy volunteers.
Interventions: Ioflupane (123I) was administered.
Outcome measures: Images were assessed by
panels of 3–5 blinded experts and/or on-site nuclear
medicine physicians, classified as normal or abnormal
and compared with clinical diagnosis (reference
standard) to determine sensitivity and specificity.
Results: Pooling the four studies, 928 participants
were enrolled, 849 were dosed and 764 completed
their study. Across all studies, when images were
assessed by on-site readers, ioflupane (123I) diagnostic
effectiveness had an overall (95% CI) sensitivity of
91.9% (88.7% to 94.5%) and specificity of 83.6%
(78.7% to 87.9%). When reads were conducted blindly
by a panel of independent experts, the overall
sensitivity was 88.7% (86.8% to 90.4%) and
specificity was 91.2% (89.0% to 93.0%).
Conclusions: In this pooled analysis, the visual
assessment of ioflupane (123I) images provided high
levels of sensitivity and specificity in detecting the
presence/absence of an SDDD. Ioflupane (123I) imaging
has the potential to improve diagnostic accuracy in
patients with signs and symptoms of a movement
disorder and/or dementia.
Trial registration number: NCT00209456.
INTRODUCTION
Despite the development of consensus clinical
diagnostic criteria,1–5 early and accurate
diagnosis of common neurodegenerative con-
ditions like Parkinson’s disease (PD) and
dementia with Lewy bodies (DLB) continues
to present challenges. Delays in diagnosis
cause unnecessary distress and uncertainty for
patients and their families, increase healthcare
use through additional appointments and
Strengths and limitations of this study
▪ This study provides the largest and most defini-
tive set of clinical evidence to date, summarising
experience from three phase 3 and one phase 4
trials with all data pooled for a new statistical ana-
lysis, N=726, showing that ioflupane (123I) single-
photon emission CT imaging has high sensitivity
and specificity for detecting the presence or
absence of a striatal dopaminergic deficit in
patients with movement disorders and dementia
(intent to diagnose and per protocol populations).
Differences among different patient populations
and inter-reader blinded image evaluation results
are reported.
▪ Well-designed, prospective studies with 12–36
months of clinical follow-up after ioflupane (123I)
imaging, in which blinded image evaluation by
3–5 independent nuclear medicine physicians
(no access to clinical information) was used for
image assessment.
▪ Studies did not have autopsy confirmation of
diagnosis (found to be impractical for up to
36 months of follow-up in the majority of
patients in early stage of the disease), though
the standard of expert clinical diagnosis, particu-
larly at follow-up after 12 months or later, is an
accepted reference standard for biomarker valid-
ation studies.
▪ Only two of the studies (PDT301 and PDT304)
used expert clinical panels to establish the clin-
ical diagnosis; the others relied on on-site inves-
tigator diagnosis (though made blind to imaging
findings, except one clinical utility study
PDT408).
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investigations and increase the risk that patients will
develop preventable disabilities.6 Not surprisingly, the
longer a patient is observed and the greater the amount of
accumulated clinical information, such as response to
medications and progression of signs and symptoms, the
greater the accuracy of the diagnosis.7 Inaccurate diagno-
ses may result in prescription of inappropriate medica-
tions, needlessly exposing patients to potentially harmful
side effects, while denying patients treatment of symp-
toms.6 Furthermore, diagnostic discrimination between
degenerative and non-degenerative diseases is important
because disease course, therapy and prognosis differ con-
siderably among patients.6 8
Differential diagnosis of movement disorders may be
confounded by presence of inconsistent parkinsonian
features and/or atypical presentation of classic symp-
toms. Differentiation of Alzheimer’s disease (AD) from
DLB is also difficult, even after multiple evaluations.
Consensus clinical criteria2–5 9 without imaging results
have good specificity (80–90%), but sensitivity is highly
variable and can be as low as 30%, with the most
common misdiagnosis being AD.9 10
The advent of in vivo visualisation of striatal dopamine
transporter using the radiopharmaceutical ioflupane
(123I) (iodine-123-fluoropropyl (FP)-carbomethoxy-3β-
(4-iodophenyltropane) (CIT) or ioflupane I123 injec-
tion or [123I] ioflupane or [123I] FP-CIT or DaTSCAN or
DaTscan, GE Healthcare, Amersham, UK) and single-
photon emission CT (SPECT) imaging has enhanced
clinicians’ ability to differentiate diseases that involve
loss of dopaminergic nigrostriatal neurons from those
that do not. Throughout this paper we will refer to these
disorders as striatal dopaminergic deficit disorders
(SDDDs), which is the clinicopathoanatomical term
used here as a group term for the clinical reference
diagnoses of parkinsonian syndrome (PS) and/or DLB,
by virtue of them being recognised as clinical disorders
that are known to have striatal dopaminergic deficit.
Ioflupane (123I) is the only approved imaging agent for
this purpose; the European Medicines Agency (EMA)
approved it under the trade name DaTSCAN (ioflupane
(123I)) in 2000,11 and the US Food and Drug
Administration (FDA) approved it under the trade name
DaTscan (ioflupane I123 injection) in 2011.12 It is cur-
rently approved in 33 countries. We searched the litera-
ture and found numerous clinical trials that have been
performed to establish the technical feasibility, diagnos-
tic effectiveness, sensitivity and specificity of ioflupane
(123I).13–43 However, each trial had limited numbers of
participants for whom results were available, ranging
from 16 to 326.37 15 Our search revealed that two
meta-analyses have been performed evaluating diagnos-
tic accuracy of SPECT imaging in DLB and in PSs.44 45
However, no previous pooled data analysis had been
undertaken and the aim of this study was to undertake a
pooled analysis using the four clinical studies that were
the large, multisite efficacy trials submitted to support
the new drug application filing in the USA (three of
them for EU) for licensing. They were conducted to the
Good Clinical Practice (GCP) standards in predefined
populations. Meta-analyses do not allow combination of
individual participant’s data; only mean values from
each study publication are used, rather than maximising
information from the raw data. Meta-analyses include all
available studies, and may include small, exploratory,
non-GCP studies; and may include tracer prototypes (eg,
non-approved tracers such as β-CIT) that are not manu-
factured to commercial tracer quality, with robust,
regulatory-accepted good manufacturing practice
processes.
Although two of our studies had been included in
each of the meta-analyses (PDT301 baseline14 in,44 and
DP008-00313 in45), the other two had not. Performing a
pooled analysis would provide a large body of evidence
on the diagnostic performance of ioflupane (123I) in
participants with movement disorders or dementia.
METHODS
Participants
The research question was to determine the pooled
diagnostic accuracy (sensitivity and specificity) of the
four trials submitted to the US FDA application for ioflu-
pane (123I).13–18 All studies tested the effectiveness of
ioflupane (123I) (for the purposes of this report, ioflu-
pane (123I) will be used throughout the paper) in
detecting the loss of dopaminergic nigrostriatal neurons
in participants with symptoms and signs of movement
disorders and/or dementia. The reference standard was
the final clinical diagnosis of a disease that is known to
have or not have a striatal dopaminergic deficit (here-
after called reference clinical diagnosis).46 This clinical
diagnosis was made blind to imaging results in three of
the four studies (phase 3 studies DP008-003, PDT301,
PDT304 (also elsewhere sometimes known as
PDT03004)). In two of the four studies (PDT301 and
PDT304), the final clinical diagnosis was made by a
panel of experts. Table 1 summarises the attributes of
the four studies. Although phase 4 study PDT408 was
designed to assess the clinical utility of ioflupane (123I)
image assessments as the primary end point, sensitivity
and specificity were secondary end points, and the
image results were included in the pooled analysis. The
investigators who participated in each of the four studies
are listed in online supplementary table S1.
All studies were conducted in accordance with the
current revision of the Declaration of Helsinki; the GCP:
Consolidated Guideline, approved by the International
Conference on Harmonisation and applicable national
and local laws. Participants or their guardians gave
written informed consent after the aims, methods,
anticipated benefits and potential hazards were
explained, and prior to starting any study procedures or
assessments. The informed consent for each study
included a provision for subsequent analyses, of which
this pooled analysis is an example. Study PDT301 is
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Table 1 Summary of studies included in pooled analysis
Principal study
DP008-003 PDT304 PDT301 PDT408
Study design ▸ Phase 3
▸ Multicentre, open-label,
non-randomised
▸ Single-dose
▸ Expert clinical diagnosis at baseline
according to published consensus
criteria as the RCD
▸ Phase 3
▸ Multicentre, open-label,
non-randomised
▸ Repeat-dose (maximum of
3)
▸ Expert clinical diagnosis at
36 months as the RCD
▸ Phase 3
▸ Multicentre, open-label,
non-randomised
▸ Single-dose
▸ Expert clinical diagnosis at 12 months
as the RCD
▸ Phase 4
▸ Multicentre, open-label, non-randomised
▸ Single-dose
▸ Expert clinical diagnosis at 24 months as the
RCD
Dates study was
conducted
▸ August 1997 to February 1998 ▸ January 1999 to June 2005 ▸ December 2003 to June 2006 ▸ November 2000 to November 2003
Population ▸ Healthy volunteers
▸ Participants with a clinical
diagnosis of:
▸ Parkinson’s disease
▸ Multiple system atrophy
▸ Progressive supranuclear palsy or
▸ Essential tremor
▸ Healthy volunteers
▸ Participants with the clinical
features of:
▸ Early Parkinson’s disease or
▸ Tremor (mainly essential
tremor)
▸ Participants with dementia (features
of possible DLB or with features of
other dementia (AD, VaD))
▸ Participants with movement disorders (an
uncertain clinical diagnosis as to PS or
non-PS)
Efficacy objectives ▸ Primary
▸ Sensitivity and specificity for
detecting or excluding an SDDD
▸ Secondary
▸ Inter-reader agreement
▸ Primary
▸ Sensitivity and specificity for
detecting or excluding an
SDDD
▸ Secondary
▸ Inter-reader agreement
▸ Primary
▸ Sensitivity and specificity for detecting
or excluding an SDDD
▸ Secondary
▸ Inter-reader agreement
▸ Primary*
▸ Impact of ioflupane (123I) image assessments
on patient diagnoses, confidence that patient
had PS, and planned management
▸ Secondary
▸ Sensitivity and specificity for detecting or
excluding an SDDD
Type of control No control used No control used No control used No control used
Investigational product Ioflupane (123I) 111–185 MBq
(3–5 mCi) iv, 1 dose
Ioflupane (123I) 111–185 MBq
(3–5 mCi) iv, 3 doses
18 months apart
Ioflupane (123I) 111–185 MBq (3–5 mCi)
iv, 1 dose
Ioflupane (123I) 111–185 MBq (3–5 mCi) iv,
1 dose (73 participants) or 2 doses 24 months
apart (14 participants)
Number of study
centres
6 10 40 15
Number of participants
enrolled
250 202 351 125
Age of ITD population,
range (mean)
40, 80 (62.7) 33, 79 (60.4) 54, 90 (73.9) 25, 84 (64.2)
Gender 62% male, 38% female 56% male, 44% female 57% male, 43% female 58% male, 42% female
Race Caucasian 98%
Black 1%
Asian <1%
Caucasian 100% Caucasian 100% Caucasian 99%
Asian 1%
Number of participants
evaluable for efficacy
220 102 288 118
Blinded reads
performed
Yes Yes Yes No
*Primary objective was to assess clinical utility of ioflupane (123I) images; however, images were used for pooled efficacy analysis.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; ITD, intent to diagnose; MBq, megabecquerel; PS, parkinsonian syndrome; RCD, reference clinical diagnosis; SDDD, striatal
dopaminergic deficit disorder; VaD, vascular dementia.
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identified in clinicaltrials.gov as NCT00209456. All other
trials began enrolling prior to 1 July 2005, the cut-off
date for the initiation of the requirement by the
International Committee of Medical Journal Editors for
trials to be registered, so are not associated with any
public database identifiers.
Procedures
All studies, including each study’s inclusion and exclu-
sion criteria, have been published13–18; a brief overview
of the methods follows. All four studies were open-label,
non-randomised, phase 3 or 4 clinical trials to deter-
mine the sensitivity (positive per cent agreement (PPA))
and specificity (negative per cent agreement (NPA)) of
ioflupane (123I) SPECT imaging to detect or exclude an
SDDD in participants with various movement disorders
(PS, including PD, multiple system atrophy (MSA) and
progressive supranuclear palsy (PSP); or essential tremor
(ET)) and/or dementia (DLB, AD or vascular dementia
(VaD)), and healthy volunteers. Participants received
either a single or repeat (up to three doses total) dose
of 111–185 MBq of ioflupane (123I). SPECT imaging was
performed between 3 and 6 h after injection. Ioflupane
(123I) images were read on-site (institutional reads), as
well as by three or five independent blinded readers
(blinded image evaluation (BIE)) in three of the
studies, and classified as normal (SDDD absent) or
abnormal (SDDD present). Abnormal images were
further classified as type 1, 2 or 3.12 Expert clinical diag-
nosis using a blinded panel of three neurologists or
dementia specialists established whether the participant
had an SDDD (PD, PS, PSP, MSA or DLB) or a
non-SDDD (ET, AD or VaD and healthy volunteers).
Expert clinical diagnosis was established at various time
points across the four studies: DP008-003 at baseline,
PDT301 at baseline and month 12, PDT408 at baseline
and month 24 and PDT304 at baseline and months 18
and 36. In PDT408, the final diagnosis was made with
access to the ioflupane (123I) SPECT images.
Each ioflupane (123I) image result was compared with
the corresponding reference clinical diagnosis, and
classified as a true-positive (TP), true-negative (TN),
false-positive (FP) or false-negative (FN) scan to allow
calculation of sensitivity and specificity. Sensitivity was
calculated as nTP/(nTP+nFN), (n=number of partici-
pants). Specificity was calculated as nTN/(nTN+nFP).
Additional efficacy end points included inter-reader
agreement between BIE readers, as well as BIE readers
versus on-site institutional readers (DP008-003, PDT304
and PDT301).
Statistical analysis
All statistical analyses were performed using Statistical
Analysis Software (SAS Institute Inc, Cary, North
Carolina, USA). Demographic data were collected and
are presented using descriptive statistics. Populations
analysed included enrolled (all participants who were
enrolled in any one of the four studies), dosed (all
enrolled participants who received ioflupane (123I)),
intent to diagnose (ITD; all dosed participants who under-
went SPECT imaging and underwent the reference clin-
ical diagnosis assessment for the relevant analysis) and
per protocol (PP; all participants in the ITD population
with no major protocol violations). Sensitivity and speci-
ficity were calculated for the ITD and PP populations,
and are reported with 95% CIs. For the purpose of this
report, we will be using sensitivity and specificity (equiva-
lent to PPA and NPA). Pairwise inter-reader and BIE
versus on-site reader agreement were analysed using
Cohen’s κ statistic. Inter-reader agreement across all BIE
readers was analysed using Fleiss’ κ statistic.
RESULTS
Participant disposition and characteristics
Participant disposition for each study and for the pooled
analysis is shown in figure 1. Of the 928 participants
enrolled, 849 (91%) were dosed, and 764 (82%) com-
pleted their study. The most common reasons for not
completing a study included participant request/with-
drew consent (85 participants, 9%), lost to follow-up (34
participants, 4%) and protocol violation (14 partici-
pants, 2%). Eleven participants (1%) did not complete
due to safety concerns, including adverse events.
Medical history data were not collected consistently
across studies and could not be pooled for this analysis.
By-study and pooled participant baseline demographics
are shown in table 2 (ITD population; PP population in
online supplementary table S3). No meaningful differ-
ences were noted in baseline demographics between the
ITD and PP populations. Age was similar in three of the
four studies, with participants in PDT301 being older—
unsurprisingly because this study only included people
with dementia. In all studies, there were more men than
women, with a similar ratio across studies. The majority
was Caucasian, with African-Americans and/or Asians
representing 1% or less in any single study. Clinical diag-
noses represented in each study are tabulated in table 2
(ITD population) and online supplementary table S4
(PP population), and are presented graphically in figure
2A (ITD population) and figure 2B (PP population).
Overall, 393 (54%) of participants in the ITD population
were classified as having SDDD (SDDD present), while
249 (34%) were classified with conditions that did not
have an SDDD (SDDD absent).
Sensitivity (PPA) and specificity (NPA)
Sensitivity and specificity for ioflupane (123I) to detect
SDDD (abnormal scan) or non-SDDD (normal scan)
using the mean of BIE reads is displayed in figure 3.
Online supplementary tables S4 and S5 (ITD and PP
populations, respectively) show the means and 95% CI
for the individual reads for PSs, DLB and total. Figure 3A
shows high sensitivity and specificity in the ITD popula-
tion for both movement disorders (PS) and the total
pooled analysis, with a slightly lower sensitivity value
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(78.5%) when assessing participants with dementia.
Sensitivity and specificity did not change substantially
when reference clinical diagnoses were made for DLB at
month 12. Sensitivity decreased when reference clinical
diagnoses were made for PS at months 18 and 36 (78.9%
and 76.6%), but specificity values increased slightly,
exceeding 95% at each time point. Overall, the sensitivity
of BIE reads of ioflupane (123I) SPECT images in the
ITD population for PS and dementia at all diagnosis time
points ranged from 76.6% to 91.1%, and specificity
ranged from 90.1% to 96.7%; PP population results
(figure 3C, D) were very similar. Figure 4A–D displays the
same analyses using the on-site read results. Overall, sen-
sitivity in the ITD population (figure 4A, B) ranged from
81.4% to 89.9%, and tended to be higher for on-site
reads compared with the BIE reads. Specificity ranged
from 81.6% to 90.3%, and tended to be lower compared
with BIE reads. No meaningful differences were noted in
the values when analysing the PP population (figure
4C, D). Tables 3 and 4 (ITD and PP populations, respect-
ively) summarise the sensitivity and specificity by expert
clinical diagnosis for on-site, institutional reads.
Inter-reader agreement
Three of the studies had BIE readers, and study PDT304
had three sets of images to be read. Overall, the
agreement between the BIE reader pairs was good, and
ranged from 0.81 (95% CI 0.73 to 0.90) to 1.00 (1.00 to
1.00). The Fleiss’ κ for all BIE readers in a study ranged
from 0.88 (0.84 to 0.92) to 0.99 (0.87 to 1.10).
Agreement between the BIE readers and the on-site
read was similar for two of the studies, and ranged from
0.82 (0.73 to 0.90) to 0.94 (0.87 to 1.01); for study
PDT301, the agreement for this comparison was not as
good, with κ ranging from 0.60 (0.51 to 0.69) to 0.68
(0.60 to 0.76). Inter-reader agreement for the PP popu-
lation was comparable to that determined for the ITD
population (data not shown).
DISCUSSION
The current pooled analysis provides the largest data set
of clinical evidence (N=726 in the ITD population) to
date showing that ioflupane (123I) SPECT imaging has
high sensitivity and specificity for detecting the presence
or absence of a striatal dopaminergic deficit in ITD and
PP population of patients with movement disorders
and/or dementia. Another strength of this study is that
we pooled well-designed, prospective studies with 12–
36 months of clinical follow-up after ioflupane (123I)
imaging in which BIE by 3–5 independent nuclear medi-
cine physicians (no access to clinical information) was
used for image assessment. Overall, sensitivity for
Figure 1 Participant disposition. AE, adverse event; ITD, intent to diagnose; PP, per protocol.
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detecting the presence or absence of an SDDD ranged
from 75% to 96.5%, and specificity ranged from 83% to
100%. Inter-reader agreement was high, with κ for
blinded reader pairs ranging from 0.81 to 1, indicating
that diagnostic accuracy is not dependent on individual
expert performance.
When BIE reads were compared with on-site reads,
specificity was higher for the BIE reads, whereas sensitiv-
ity was higher for the on-site reads. BIE versus on-site
reader agreement was lower in the PDT301 study. This
study focused on participants with dementia, whereas
the other studies focused primarily on participants with
movement disorders. Clinical diagnosis of DLB tends to
be less accurate than PS.10 13 16 47 On-site readers had
access to patient clinical information, whereas BIE
readers did not. This likely contributed to the observed
increase in sensitivity and decrease in specificity when
images were read by the on-site readers compared with
BIE readers, resulting in lower agreement between the
two reader groups in this study.
A limitation of this study is that the four studies in the
pooled analysis used expert clinical diagnosis as a refer-
ence standard for the presence or absence of an SDDD.
Two of the studies (PDT301 and PDT304) used expert
panels to establish the clinical diagnosis. In DP008-003,
enrolled participants had established diagnoses, so an
expert panel was not considered necessary. In PDT408,
the final diagnosis was made with access to the ioflupane
(123I) SPECT images, which was required to assess the
test clinical utility. The truth standard for diagnosing
movement disorders and dementia is neuropathological
confirmation of brain tissue at autopsy. However, with a
slowly progressive, mostly benign course of these disor-
ders, these patients are unlikely to die during the course
of relatively short clinical trial duration and be partici-
pants for autopsy assessment. Previous postmortem
studies demonstrated a good correlation between ioflu-
pane (123I) SPECT imaging with neuropathological find-
ings.19 46 In a study by Walker et al,19 when validation
was by autopsy diagnosis, sensitivity and specificity of
initial clinical diagnoses in DLB were 75% and 42%,
respectively, whereas sensitivity and specificity of ioflu-
pane (123I) imaging were higher, with values of 88% and
83%, respectively (88% and 100% for semiquantitative
analysis of scans). Therefore, the use of clinical diagno-
sis as the non-perfect reference standard rather than
neuropathological confirmation at autopsy may have
contributed to the sensitivity and specificity values
obtained in this pooled analysis. Another limitation of
the study is that study PDT408 was not designed specific-
ally to assess the sensitivity and specificity of ioflupane
(123I) SPECT imaging for detecting or excluding an
Table 2 Demographic characteristics and clinical diagnosis (per reference clinical diagnosis) by study—ITD population
(N=726)
Study
Total (N=726)DP008-003 (N=220) PDT304 (N=102) PDT301 (N=326) PDT408 (N=78)
Age (year)
Mean (SD) 62.7 (8.87) 60.4 (10.91) 73.9 (7.17) 64.2 (11.99) 67.6 (10.60)
Minimum, Maximum 40, 80 33, 79 54, 90 25, 84 25, 90
Median 63.5 61.0 75.0 67.0 69.0
Gender
Male 136 (62%) 57 (56%) 187 (57%) 41 (53%) 421 (58%)
Female 84 (38%) 45 (44%) 139 (43%) 37 (47%) 305 (42%)
Race
Caucasian 216 (98%) 102 (100%) 326 (100%) 77 (99%) 721 (99%)
Black 3 (1%) 0 (0%) 0 (0%) 0 (0%) 3 (<1%)
Asian 1 (<1%) 0 (0%) 0 (0%) 1 (1%) 2 (<1%)
Other 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PS (SDDD) 158 (72%) 71 (70%) 0 (0%) 48 (62%) 277 (38%)
Possible PS 158 (72%) 5 (5%) 0 (0%) 48 (62%) 211 (29%)
Probable PS 0 (0%) 66 (65%) 0 (0%) 0 (0%) 66 (9%)
DLB (SDDD) 0 (0%) 0 (0%) 116 (36%) 0 (0%) 116 (16%)
Possible DLB 0 (0%) 0 (0%) 27 (8%) 0 (0%) 27 (4%)
Probable DLB 0 (0%) 0 (0%) 89 (27%) 0 (0%) 89 (12%)
Non-PS/non-DLB (no SDDD) 62 (28%) 31 (30%) 126 (39%) 30 (38%) 249 (34%)
ET 27 (12%) 14 (14%) 0 (0%) 23 (29%) 64 (9%)
AD 0 (0%) 0 (0%) 125 (38%) 0 (0%) 125 (17%)
Other 35 (16%) 17 (17%) 1 (<1%) 7 (9%) 60 (8%)
SDDD present* 158 (72%) 71 (70%) 116 (36%) 48 (62%) 393 (54%)
SDDD absent 62 (28%) 31 (30%) 126 (39%) 30 (38%) 249 (34%)
*Includes possible and probable PS and possible and probable DLB diagnoses.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; ET, essential tremor; ITD, intent to diagnose; N, number of participants in the
study; PS, parkinsonian syndrome; SDDD, striatal dopaminergic deficit disorder.
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SDDD. However, they were secondary end points, and
expert clinical diagnosis and ioflupane (123I) images
were available on these participants, so it was deemed
appropriate to include this study in the pooled analysis.
Of note, the sensitivity and specificity values for this
study fell within the range for the other three studies in
which clinical diagnoses were made blinded to ioflupane
(123I) images, and exclusion of this study would not have
altered the main findings reported here.
Substantial clinical need has been established for an
adjunct to existing diagnostic tools for differentiating PD
from ET, and DLB from AD. Examiner expertise affects
Figure 2 Summary of clinical
diagnosis (per reference clinical
standard) by study. (A) ITD
population. (B) PP population.
AD, Alzheimer’s disease; DLB,
dementia with Lewy bodies; ET,
essential tremor; ITD, intent to
diagnose; PP, per protocol; PS,
parkinsonian syndrome; SDD,
striatal dopaminergic deficit.
Figure 3 Summary of sensitivity (PPA) and specificity (NPA) by expert clinical diagnosis—mean of blind reads. (A) ITD
population—summary results calculated across all studies and readers at baseline. DLB is calculated based on probable DLB
versus non-DLB. Total is calculated based on SDDD present versus SDDD absent. (B) ITD population—DLB at month 12
calculated for all readers in study PDT301. PS at month 18 and 36 calculated for all readers in study PDT304. (C) PP population
—summary results calculated across all studies and readers at baseline. DLB is calculated based on probable DLB versus
non-DLB. Total is calculated based on SDDD present versus SDDD absent. (D) PP population—DLB at month 12 calculated for
all readers in study PDT301. PS at month 18 and 36 calculated for all readers in study PDT304. DLB, dementia with Lewy
bodies; ITD, intent to diagnose; NPA, negative per cent agreement; PP, per protocol; PPA, positive per cent agreement; PS,
parkinsonian syndrome; SDDD, striatal dopaminergic deficit disorder.
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diagnostic accuracy, with subspecialists having the
highest accuracy, followed by general neurologists;
primary care physicians tend to have the lowest.48 In a
general practice setting (N=202), 15% of patients who
had been diagnosed with parkinsonism had tremor with
onset after the age of 50, or who had ever received par-
kinsonism drugs had their diagnosis unequivocally
rejected when strict clinical diagnostic criteria were
applied and they completed a detailed neurological
interview.23 On the other hand, 13 patients (19%) not
previously diagnosed with PD received this diagnosis fol-
lowing use of strict clinical diagnostic criteria.49 In
another general practice setting in Scotland (N=610),
5% of patients taking antiparkinson therapy for a diag-
nosis of PD had their medication successfully withdrawn
following evaluation by two movement disorder specia-
lists; ioflupane (123I) scanning was performed if there
was uncertainty.50 General neurologists changed the
diagnosis in 75% and movement disorder specialists in
47% of clinically uncertain PS cases after ioflupane
(123I) imaging results became available.6 51 These
studies highlight the frequency of PD or PS misdiag-
nosis, and illustrate how using ioflupane (123I) scanning
can result in corrections to treatment. Early diagnosis is
confounded by the fact that these diseases are progres-
sive, and it may take time for the signs and symptoms to
worsen until they clearly point to one disease.7 The
choice of consensus criteria also affects the sensitivity
and specificity of the clinical diagnosis.52 53 All these
factors contribute to clinical diagnosis failing to align
with autopsy findings up to 25% of the time.52 Ioflupane
(123I) SPECT imaging does not diagnose disease; rather,
it is used to determine the presence or absence of a stri-
atal dopaminergic deficit. The performance of ioflu-
pane (123I) reported here may have been lower than
expected, particularly in patients with DLB, because we
were comparing it to clinical diagnosis based on consen-
sus criteria, known to be imprecise.
Regulatory approval of ioflupane (123I) in Europe and
the USA has facilitated meeting the clinical need to
improve the accuracy of clinical diagnosis. Adoption and
utilisation of this new technology is expanding, and
several professional societies and organisations are sup-
porting ioflupane (123I) imaging as a useful and vali-
dated diagnostic tool. These include mention in the
2013 EFNS/MDS-ES/ENS guideline (Category A),54 the
Society of Nuclear Medicine,55 the UK’s National
Institute for Health and Care Excellence (NICE) 2006
guidance,56 the Scottish Intercollegiate Guidelines
Network (SIGN)57 and the EFNS-ENS guidelines.4 The
Parkinson Progression Marker Initiative (PPMI) is
adding ioflupane (123I) imaging to be included in study
inclusion criteria, as well as during a 5-year study of PD
biomarker progression.58
Research is needed to more fully elucidate future
applications of ioflupane (123I) SPECT imaging. While
not currently licensed for this application, discussions
have recently focused on the possibility of whether quan-
titative analysis of ioflupane (123I) binding might further
increase the sensitivity and specificity of SDDD detection
and enable differentiation of other PS, such as PSP, MSA
or vascular parkinsonism from PD.20 59 60 Additional
studies that compare ioflupane (123I) imaging results
with postmortem neuropathology rather than expert clin-
ical diagnosis may document better the accuracy of esti-
mates of sensitivity and specificity. Our use of expert
clinical diagnosis as the standard of truth, while vali-
dated, was not as perfect as autopsy. In addition, not all
patients with DLB have nigrostriatal degeneration, and a
small percentage of these patients may have primarily
cortical degeneration.61 Finally, ioflupane (123I) imaging
may be helpful in identifying dopaminergic nigrostriatal
Figure 4 Summary of sensitivity (PPA) and specificity (NPA) by expert clinical diagnosis—on-site institutional reads. (A) ITD
population—summary results calculated across all studies and time points. For PDT301, month 12 reference clinical diagnosis
was used in this analysis. DLB is calculated based on probable DLB versus non-DLB. Total is calculated based on SDDD
present versus SDDD absent. (B) ITD population—DLB at month 12 calculated for on-site readers in study PDT301. PS at month
18 and 36 calculated for on-site readers in study PDT304. (C) PP population—summary results calculated across all studies and
time points. For PDT301, month 12 reference clinical diagnosis was used in this analysis. DLB is calculated based on probable
DLB versus non-DLB. Total is calculated based on SDDD present versus SDDD absent. (D) PP population—DLB at month 12
calculated for on-site readers in study PDT301. PS at month 18 and 36 calculated for on-site readers in study PDT304. DLB,
dementia with Lewy bodies; ITD, intent to diagnose; NPA, negative per cent agreement; PP, per protocol; PPA, positive per cent
agreement; PS, parkinsonian syndrome; SDDD, striatal dopaminergic deficit disorder.
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Table 3 Summary of sensitivity (PPA) and specificity (NPA) by expert clinical diagnosis—on-site institutional reads—ITD population (N=726)
Response
Expert clinical diagnosis
PS; SDDD DLB; SDDD Total
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
(%, 95% CI) (%, 95% CI) (%, 95% CI) (%, 95% CI) (%, 95% CI) (%, 95% CI)
Pooled studies* 93.1 (89.5 to 95.8) 91.1 (84.6 to 95.5) 88.3 (80.0 to 94.0) 77.4 (69.7 to 83.9) 91.9 (88.7 to 94.5) 83.6 (78.7 to 87.9)
Study PDT301—month 12 89.9 (81.7 to 95.3) 81.6 (73.7 to 88.0)
Study PDT304—month 18 81.4 (70.3 to 89.7) 90.3 (74.2 to 98.0)
Study PDT304—month 36 83.8 (72.9 to 91.6) 86.2 (68.3 to 96.1)
Mean results† 89.6 (86.3 to 92.4) 90.2 (84.9 to 94.1) 89.9 (81.7 to 95.3) 81.6 (73.7 to 88.0) 89.7 (86.7 to 92.2) 86.7 (82.4 to 90.3)
Sensitivity/specificity for DLB is calculated based on probable DLB versus non-DLB.
Sensitivity/specificity for total is calculated based on SDDD versus non-SDDD.
*Pooled studies include on-site ioflupane (123I) reads for DP008-003, PDT304 (at baseline), PDT301 (baseline reference clinical diagnosis) and PDT408.
†Summary results calculated across all studies and time points. For PDT301, the month 12 reference clinical diagnosis was used.
DLB, dementia with Lewy bodies; ITD, intent to diagnose; NPA, negative per cent agreement; PPA, positive per cent agreement; PS, parkinsonian syndrome; SDDD, striatal dopaminergic deficit
disorder.
Table 4 Summary of sensitivity (PPA) and specificity (NPA) by expert clinical diagnosis—on-site institutional reads—PP population (N=622)
Response
Expert clinical diagnosis
PS; SDDD DLB; SDDD Total
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
(%, 95% CI) (%, 95% CI) (%, 95% CI) (%, 95% CI) (%, 95% CI) (%, 95% CI)
Pooled studies* 91.8 (87.5 to 95.0) 90.3 (82.9 to 95.2) 87.5 (78.7 to 93.6) 77.1 (69.3 to 83.7) 90.6 (86.8 to 93.6) 82.6 (77.3 to 87.1)
Study PDT301—month 12 89.4 (80.8 to 95.0) 81.3 (73.3 to 87.8)
Study PDT304—month 18 80.9 (69.5 to 89.4) 90.3 (74.2 to 98.0)
Study PDT304—month 36 83.3 (72.1 to 91.4) 86.2 (68.3 to 96.1)
Mean results† 88.2 (84.5 to 91.3) 89.6 (83.8 to 93.8) 89.4 (80.8 to 95.0) 81.3 (73.3 to 87.8) 88.4 (85.1 to 91.2) 86.0 (81.4 to 89.8)
Sensitivity/specificity for DLB is calculated based on probable DLB versus non-DLB.
Sensitivity/specificity for total is calculated based on SDDD versus non-SDDD.
*Pooled studies include on-site [123I] FP-CIT reads for DP008-003, PDT304 (at baseline), PDT301 (baseline reference clinical diagnosis) and PDT408.
†Summary results calculated across all studies and time points. For PDT301, the month 12 reference clinical diagnosis was used.
DLB, dementia with Lewy bodies; FP-CIT, fluoropropyl-carbomethoxy-3β-(4-iodophenyltropane); NPA, negative per cent agreement; PP, per protocol; PPA, positive per cent agreement; PS,
parkinsonian syndrome; SDDD, striatal dopaminergic deficit disorder.
O
’Brien
JT,etal.BM
J
Open
2014;4:e005122.doi:10.1136/bm
jopen-2014-005122
9
O
p
e
n
A
c
c
e
s
s
 
group.bmj.com
 o
n
 O
ctober 15, 2014 - Published by 
bmjopen.bmj.com
D
ow
nloaded from
 
degeneration in the prodromal stages, such as
rapid-eye-movement sleep behaviour disorder of
α-synucleinopathies (PD, MSA, DLB) and tauopathies
(PSP, corticobasal degeneration).62 63
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